What Fleboton Treats: Main Uses and Benefits

This combination medicine is commonly used to help manage the symptomatic discomfort associated with compromised vascular integrity and microcirculatory distress. It is primarily relevant for easing symptoms related to Chronic Venous Insufficiency (CVI) and managing acute episodes of hemorrhoidal disease. The combination is applied in clinical settings that involve acute or unstable symptom patterns.

It is used in situations involving certain distressing symptoms, including persistent leg swelling (edema), feelings of heaviness, venous ache, and acute manifestations like localized bleeding and inflammation. It is relevant for easing symptoms linked to capillary fragility and provides supportive relief that helps patients cope more steadily with symptom fluctuations.

“The primary goal is providing symptomatic relief that helps patients cope more steadily with difficult episodes and assists with maintaining functional stability.”

Key Use: Symptomatic Management of Venous and Hemorrhoidal Discomfort The medicine is commonly used to help with symptomatic relief for both chronic symptoms of venous stasis and acute, disruptive manifestations of hemorrhoidal disease.

This section summarizes the official eligibility profile for Fleboton (Carbazochrome 1.5 mg + Troxerutin 150 mg) as defined in regulatory documentation, such as the Summary of Product Characteristics (SmPC).

Populations for Whom Use is Prohibited or Restricted

Classification	Eligibility Constraint
Contraindicated	Individuals with known hypersensitivity or allergy to the active substances (Carbazochrome, Troxerutin) or to any inactive component (excipients) in the formulation.
Conditional Use	Pregnancy: Use requires caution and a professional risk assessment. Official data on human pregnancy exposure are unavailable, though animal studies have not indicated direct harm.
Use Not Established	Pediatric Patients: Safety and efficacy have not been formally established, and the medicine is not generally approved for use in children.
Route Restriction	Use is not approved for certain administration methods, such as the intradermic or subcutaneous route (mesotherapy), due to a lack of controlled clinical studies supporting efficacy and safety via these routes.

The regulatory documentation strictly defines patient eligibility based on these criteria. The primary exclusion is the contraindication due to prior immune response. Other constraints result from the absence of definitive clinical data in specific patient groups (pediatric) or administration contexts (unapproved routes), leading to restrictions on use.

Interactions with other medicines and products

This section describes the officially documented interaction patterns for Fleboton (Carbazochrome and Troxerutin Solution for Injection) as stated in government regulatory sources.

Systemic Drug-Drug Interactions

Official prescribing information for the fixed-dose combination product confirms that no systemic pharmacokinetic or pharmacodynamic drug-drug interactions are formally reported with other medicinal products. The regulatory review of the combination does not document any known interactions involving enzyme pathways (such as Cytochrome P450) or drug transporters that would alter exposure levels (AUC or Cmax) of the active ingredients.

Interactions with Food, Alcohol, and Supplements

No specific interaction patterns or constraints related to food, alcohol, herbal products, or dietary supplements are formally reported in the regulatory documentation for this medicine.

Administration-Related Restriction

The primary interaction-related restriction is a procedural constraint tied to the parenteral form. The Fleboton solution for injection is subject to a mandatory physical incompatibility rule: it must not be mixed with ascorbic acid (Vitamin C) in the same syringe or infusion. This is a crucial constraint that governs the preparation and method of administration.

Population-Specific Notes

The official label does not document any population-specific interaction cautions, such as enhanced interaction risk or altered severity in patients with hepatic impairment or in the elderly.

Fleboton's principal molecular targets are the alpha-1 (alpha1) and alpha-2 (alpha2) adrenergic receptors within the systemic vasculature. It functions as a reversible, competitive antagonist at both receptor subtypes, preventing the binding and activation by endogenous catecholamines.

At the cellular level, the blockade of alpha1-adrenergic receptors on vascular smooth muscle cells inhibits the Gq protein-mediated signaling pathway. This prevents the subsequent activation of Phospholipase C ( PLC), leading to a diminished production of Inositol Trisphosphate ( IP3) and Diacylglycerol ( DAG). The downstream cascade involves a reduction in IP3-mediated release of intracellular calcium ( Ca^2+) from the sarcoplasmic reticulum. The net intracellular consequence is a decrease in the Ca^2+-calmodulin complex formation, leading to reduced activation of myosin light chain kinase ( MLCK).

This molecular and intracellular pathway dampens the contractile signaling within the vascular smooth muscle. The system-level physiological consequence of this generalized inhibition of vasoconstriction is an increase in vascular lumen diameter and a reduction in peripheral vascular resistance.

How to use Fleboton: Administration Guidelines

This section summarizes the instructions for the use of Fleboton (Troxerutin 150 mg + Carbazochrome 1.5 mg). All administration must be performed by a healthcare professional.

---

Administration Scope

Classification	Rule
Route of administration	Intramuscular injection (I.M.)
Formulation	3 ml ampoules containing 150 mg Troxerutin and 1.5 mg Carbazochrome
Dosing Rule	The regimen described is a 3 ml ampoule (150 mg/1.5 mg fixed combination).
Frequency and Timing	Administration is typically twice a day (b.i.d.).

---

Procedural Structure

The procedural structure for administering Fleboton (I.M. injection) consists of the following general steps:

• Preparation: The product is supplied as a solution for injection in 3 ml ampoules, requiring no dilution or reconstitution prior to use.
• Administration: The full contents of the 3 ml ampoule are administered via the intramuscular route (I.M.).
• Duration: The course length is typically five consecutive days, with the administration occurring twice daily.

---

Connection to the Overall Use Protocol

Standard procedural parameters for using this fixed-combination product define a specific parenteral route and a structured short-term schedule. The protocol is centered on the twice-daily intramuscular administration of a pre-filled 3 ml ampoule, establishing a non-oral, scheduled treatment course. No preparation steps beyond standard aseptic technique are detailed for the ampoule contents, as it is a solution for injection. This regimen defines the procedural parameters of use without providing information on the therapeutic context or patient selection criteria.

Research evidence / Overview of studies for Fleboton

Evidence for use in Acute Hemorrhoidal Disease and Post-Surgical Status

Research into Fleboton, a fixed combination of carbazochrome and troxerutin, was evaluated in research exploring conditions involving periods of heightened symptoms, such as acute hemorrhoidal disease. Studies have been conducted during periods of increased symptom activity in adult patients with uncomplicated hemorrhoids and also in those immediately following hemorrhoidectomy (a post-surgical setting).

These studies mainly consisted of Randomized Controlled Trials (RCTs) and controlled clinical trials, where the combination product was evaluated in comparison to an inactive substance (placebo) or one of the individual components. The research examined outcomes related to physical discomfort, such as patient-reported outcomes describing perceived discomfort related to pain, bleeding, and edema over time.

The evidence describes patterns observed in the studies during these acute phases. Research provides insight into short-term changes and evidence provides context for symptom patterns during these acute phases. However, research is ongoing, and data for long-term prevention of future symptomatic flare-ups remain insufficient.

Evidence for use in Chronic Venous Insufficiency (CVI)

The combination product was studied in research contexts involving CVI, which is a condition characterized by functional limitations and symptoms that may vary in intensity, such as leg heaviness and ache. Studies focusing on this indication included controlled clinical trials and draw context from research available for the individual components.

The research examined outcomes reflecting daily functioning and localized discomfort, including objective measurements of edema via circumference measures. Studies also monitored subjective symptoms like leg ache.

Findings from the general class of phlebotonics, including troxerutin, studies contribute to the broader evidence landscape for CVI. However, evidence quality varies across studies, and the findings may rely partly on data from the individual components rather than exclusively from trials of the fixed combination.

Study Duration and Follow-up Data

Follow-up durations observed in the available research vary depending on the condition studied. Trials concerning episodic or acute changes related to hemorrhoids typically involve monitoring patients for limited time intervals, such as five days post-surgery or one week during an acute phase.

For chronic conditions like CVI, the research exploring short-term symptom changes often involves studies observing responses over defined time intervals that last a few weeks to a few months. Long-term effects are not fully established. There are limited data available to describe whether the observed patterns continue over long periods, or whether research examines progression of the underlying conditions.

Evidence in Specific Patient Groups and Subgroups

The research examined primarily adult patients presenting with the studied conditions. The original controlled trials were observed in non-surgical adult patients with acute hemorrhoids, as well as those in a post-surgical setting.

Data for certain groups remain insufficient. For instance, women who are pregnant or lactating were excluded from key clinical trials, meaning evidence is limited to establish how the product may be observed in these populations. Similarly, there is limited information for pediatric or adolescent patient groups.

Evidence Gaps and Areas of Uncertainty

The studies contribute to the broader evidence landscape, but certainty remains low because some research findings may rely on the general class of compounds (flavonoids/phlebotonics) rather than exclusively on the fixed combination of carbazochrome and troxerutin.

Since the primary outcomes examined were symptomatic and short-term, there is limited information for long-term outcomes to describe whether the observed patterns continue over years, or whether research examines progression of the underlying conditions. Study results reflect the specific conditions under which they were conducted, and findings describe group patterns, not personal outcomes.

Key Studies & References

1. Anatomical Therapeutic Chemical (ATC) Classification System – B02BX: Other systemic hemostatics

Common questions about Fleboton (FAQ)

---

Q: What does Fleboton treat besides its main use?

According to official product information, the medicine is used for the symptomatic treatment of conditions that affect vascular integrity. These include Chronic Venous Insufficiency and the acute phases of Hemorrhoidal Disease, as well as use in post-surgical settings.

---

Q: How quickly should someone expect Fleboton to start working?

Studies examining its use in acute conditions, such as following surgery, have indicated that initial improvements in measured outcomes began to be observed starting from the second day after administration. This information describes the timeframe for initial observed changes in the study groups.

---

Q: Is Fleboton safe to take long-term?

The official administration instructions define a specific short-term treatment period, typically five consecutive days. Regulatory documents state that data for long-term use, especially concerning safety and sustained benefits, are not fully established.

---

Q: What are the most common side effects of Fleboton?

According to official documents, the documented undesirable effects primarily include local and generalised erythema, which is a reddening of the skin. The safety profile focuses mainly on local and generalised erythema. For a complete list of possible undesirable effects, refer to the official prescribing information.

---

Q: Can Fleboton cause headaches?

Headaches and dizziness are effects that have been reported occasionally in clinical experience related to the active components of the medicine. These effects are noted in official product materials as part of clinical experience.

---

Q: Does Fleboton make you feel drowsy?

Regulatory documentation, including sections on the ability to drive and use machinery, indicates that the product has no known influence on causing drowsiness or affecting alertness.

---

Q: Does Fleboton affect sleep patterns?

Regulatory data specifically indicates that the component Carbazochrome does not have a known influence on sleep patterns.

---

Q: Can I take Fleboton if I also take a multivitamin?

While no systemic interactions with general supplements are formally reported, official product information includes a critical procedural constraint. The injection solution is physically incompatible with ascorbic acid (Vitamin C) and is subject to the mandatory constraint of not being combined with it in the same syringe.

---

Q: Does Fleboton interfere with birth control pills?

Official regulatory texts confirm that no systemic pharmacokinetic or pharmacodynamic drug-drug interactions are formally reported with other medicinal products. Since no systemic interactions are formally reported, interference with oral contraceptives is not noted in the official materials.

---

Q: How often do people need to take Fleboton for maintenance?

The documented and official regimen for this medicine defines a structured, short-term treatment course of five consecutive days. Official guidelines do not establish or recommend a maintenance or long-term preventative regimen.

---

Q: Is it normal to feel [mild, non-specific side effect] when starting Fleboton?

Clinical experience notes that some patients may experience temporary effects such as mild pain at the injection site or minor gastrointestinal effects like nausea or diarrhea when beginning treatment. These effects are described as part of the known safety profile.

---

Q: Are there different forms of Fleboton (e.g., tablet, liquid)?

The regulatory label defines this product, Fleboton, as specifically being a Solution for Injection supplied in ampoules. Other dosage forms, such as oral tablets or capsules, are not approved for this fixed combination.

---

Q: Does Fleboton contain any common allergens like gluten or lactose?

Official documentation states that the medicine is strictly contraindicated only for individuals with a known hypersensitivity to the active ingredients or to any of the inactive components (excipients). Specific details about excipients, including the presence or absence of common allergens like gluten or lactose, are included in the full official product information.

---

Q: Is Fleboton safe for older adults (seniors)?

Official documentation does not specify a separate safety profile or dosing regimen for older adults. Treatment in this population is generally based on the standard adult regimen, and no specific cautions are documented for the elderly alone.

---

Q: Can people with liver problems use Fleboton?

Official warnings state that caution should be exercised in patients with liver problems. This is because official data on the effect of the medicine or the need for dose adjustment in individuals with hepatic impairment is not available.

---

Q: Is there a generic version of Fleboton available?

The active ingredients, Troxerutin and Carbazochrome, are commonly available as generic names. This fixed combination is also sold under several different brand names internationally, such as Fleboside.

---

Q: Is Fleboton a controlled substance?

The active ingredients in Fleboton are not classified as controlled substances under major international regulatory schedules.

---

Q: Are there any specific lifestyle changes needed while taking Fleboton?

No specific dietary restrictions or mandatory lifestyle changes are documented in the official regulatory label for the use of this medicine.

---

Q: What kind of warnings are listed on the official Fleboton documents?

Official warnings include the requirement for caution in pregnant women due to a lack of available human data. The documents also strictly mandate that the product is administered only via the intramuscular route as a regulatory requirement to prevent potential localized skin reactions.

---

Q: Can Fleboton affect blood test results?

Clinical studies monitoring patients who received the fixed combination reported that administration of the medicine did not affect standard blood coagulation test results.

---

Q: Is Fleboton a prescription-only medicine?

Due to its formulation as an injection solution and its regulatory status, this medicine is typically prescribed by a healthcare provider. It is not generally available for purchase without a prescription.

---

Q: Where can I find the official regulatory information about Fleboton?

Official product information is available directly from the governmental regulatory agencies or health authorities that approved the product for use in your specific region. This information is typically provided in the form of a Summary of Product Characteristics (SmPC) or a patient information leaflet.

How to Store and Dispose of Fleboton

Fleboton (Carbazochrome/Troxerutin Solution for Injection) must be stored under specific regulatory conditions to maintain its stability. The product must be kept refrigerated at a temperature range of 2 C to 8 C (36°F to 46°F). It is mandatory to protect the solution from light by keeping the ampoules in the original outer carton.

Do not freeze the medicine. Freezing can compromise the sterile solution and its container integrity. Like all medications, Fleboton must be stored strictly out of the sight and reach of children.

For disposal, all used needles, syringes, and broken ampoules must be placed immediately in a puncture-resistant sharps disposal container. Any unused or expired medicine must not be disposed of in household waste or wastewater; instead, utilize a local authorized pharmaceutical take-back program.